ARS Pharma's Payer Setback Highlights Innovation's Costly Toll

SAN DIEGO, CA – June 24, 2026 – For any company launching a disruptive technology, the path from innovation to market dominance is fraught with obstacles. For ARS Pharmaceuticals, that obstacle has a name: commercial health insurance. The biopharmaceutical firm announced today that its groundbreaking needle-free epinephrine nasal spray, neffy, failed to secure any new commercial formulary additions in the critical July 1 coverage cycle, a significant setback in its quest to reshape the emergency allergy treatment market.

The news casts a harsh light on the foundational forces governing healthcare economics, where a product's clinical value and patient preference often collide with the fiscal realities of pharmacy benefit managers (PBMs) and insurers. While ARS Pharma is putting on a brave face, the development forces a strategic recalibration, pushing the company to tighten its belt and place a greater emphasis on its future pipeline, even as its flagship product struggles for prime-time access.

The Payer Gauntlet

The challenge of securing broad market access is a familiar story in the pharmaceutical world, but it's particularly acute for ARS Pharma. Neffy represents a major leap forward from the needle-based auto-injectors that have dominated the anaphylaxis market for decades. By offering a simple nasal spray, the company aims to overcome the "fear of the needle" and usage hesitation that plagues products like EpiPen, potentially saving lives.

Yet, innovation alone doesn't guarantee a spot on an insurer's preferred drug list. Despite ongoing discussions that stretched into mid-June, key commercial payers have deferred coverage. While the company did not name specific entities, previous investor updates from May pointed to a proposal in the "final stages" with CVS Caremark for inclusion on its commercial formulary. Today's announcement strongly implies that this key addition did not materialize for the July 1 target date, leaving neffy on the outside looking in for a significant portion of commercially insured patients.

In response, the company is leaning on a multi-pronged access strategy. It highlights that neffy remains available through a combination of existing direct coverage and a retail cash program that caps the price at $199 for patients whose claims are denied. "Every day, more patients and caregivers are choosing neffy to protect against life-threatening allergic reactions," said Richard Lowenthal, Co-founder and CEO of ARS Pharma, in a statement, emphasizing that demand continues to grow regardless of the formulary hurdles.

There was a silver lining in the public sector. Florida's Medicaid program added neffy to its unrestricted formulary, joining eight other state plans and signaling a willingness within government-funded healthcare to embrace the needle-free alternative. The company aims to have a majority of state Medicaid plans on board by early 2027, creating a crucial access channel.

A Disciplined Pivot to Profitability

Confronted with slower-than-hoped commercial uptake, ARS Pharma is making decisive moves to shore up its financial position. The company announced it is slashing its full-year 2026 cash-based operating expenses to approximately $248 million, a move reflecting "prioritized commercial investment and enhanced cost discipline."

This financial maneuvering is critical. The San Diego-based firm is burning through cash as it funds a national commercial launch, with Selling, General, and Administrative (SG&A) expenses reaching $72.2 million in the first quarter of 2026 alone. While it posted a strong $17.5 million in U.S. net product revenue for neffy in the same quarter, the company also reported a net loss of $60.6 million.

Despite these pressures, management reaffirmed its target to reach cash-flow breakeven in 2027. This confidence is built on the belief that neffy's base business, supported by growing prescriber adoption and the new cash-pay options, will provide a sustainable revenue stream. As of March 31, the company held $201.0 million in cash and equivalents, which it believes is a sufficient runway to reach that breakeven milestone. The strategy is clear: survive the market access winter by controlling costs while building a loyal user base, betting that payers will eventually follow patient and physician demand.

The Next Frontier: A Billion-Dollar Bet on Hives

Perhaps the most crucial part of ARS Pharma's long-term strategy lies not with anaphylaxis, but with a chronic and debilitating skin condition. The company is leveraging its intranasal epinephrine technology to develop a treatment for acute flares of chronic spontaneous urticaria (CSU), a condition characterized by severe, recurring hives and swelling that affects an estimated 1.6 million people in the U.S.

The global market for CSU therapies is already valued at over $2 billion and is projected to grow exponentially, making it a lucrative target. Currently, patients manage flares with antihistamines or corticosteroids, but there is no approved rapid-acting treatment specifically for these acute episodes. ARS Pharma's candidate, if successful, could be the first of its kind.

All eyes are now on the fourth quarter of 2026, when the company expects to release interim data from its Phase 2b clinical trial. The study is testing two doses of intranasal epinephrine against a placebo in patients who experience frequent, severe flares despite being on chronic medication. Positive results would not only validate the scientific approach but would also serve as a powerful signal to investors that ARS Pharma is more than a one-product story. A successful trial could pave the way for a pivotal Phase 3 study in mid-2027, positioning the company to tap into a massive unmet medical need.

This pipeline diversification is a classic biopharma hedge, using the revenue from an initial product to fund the development of future growth drivers. For ARS Pharma, the CSU program is now more than just a promising asset; it's a critical component of a narrative that must convince the market of its long-term viability. The company is banking that the strength of its core technology platform will ultimately transcend the market access challenges of a single product.

The path forward is a tightrope walk. The company must continue to demonstrate growing demand for neffy, proving to reluctant payers that it is a must-have, not a nice-to-have. First-quarter data showed promising traction, with the number of prescribing physicians reaching 28,000 and the patient count hitting 120,000. An FDA decision in March to remove age restrictions for the 1 mg dose further expanded the addressable market. Now, ARS Pharma must prove it can convert that grassroots momentum into the formulary wins that unlock a product's true commercial potential, all while nurturing the pipeline asset that may one day eclipse it.